Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

home / publications / supplement / biosimilars-for-immune-mediated-inflammatory-diseases-2022-update

Participating Faculty: Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

November 1st 2022

Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

Sonia T. Oskouei, PharmD

November 1st 2022

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

Vibeke Strand, MD;Colby Evans, MD;Allan Gibofsky, MD, JD

November 1st 2022

Biosimilar medicines: what are they and how are they used?

Vibeke Strand, MD;Colby Evans, MD;Allan Gibofsky, MD, JD

November 1st 2022

Plain Language Summary

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD

November 1st 2022

What do patients and health care providers still need to know about biosimilar medicines?

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD

November 1st 2022

Plain Language Summary

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

Allan Gibofsky, MD, JD;Colby Evans, MD;Vibeke Strand, MD

November 1st 2022

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

Colby Evans, MD;Allan Gibofsky, MD, JD;Vibeke Strand, MD

November 1st 2022

What are the current challenges to wider biosimilar use in the United States?

Colby Evans, MD;Allan Gibofsky, MD, JD;Vibeke Strand, MD

November 1st 2022

Plain Language Summary

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions